Appendices3 Reference Pages
Section 5 of 5 • Diagnostics

Appendices: Noninvasive Composite Scores, Monitoring & Biopsy Guide

Combined blood-plus-imaging composite scores (MEFIB, MAST, FAST, Agile 3+, Agile 4), longitudinal outcome monitoring, liver biopsy pathology translation, and NIT confounders.

What This Means for Patients

Combining a blood test with an imaging scan often sharpens accuracy beyond either test alone — that's the idea behind composite scores like FAST, Agile 3+, Agile 4, MAST, and MEFIB. Here you will also find longitudinal risk thresholds, a plain-English decoder for liver biopsy pathology reports (NAS 0–8 vs. F0–F4), and a single pre-test checklist showing what can artificially skew your lab or FibroScan numbers.

Parameters, target stages, rule-out and rule-in cutoffs, sensitivity, and specificity for MEFIB, MAST, FAST, Agile 3+, and Agile 4.

Longitudinal prognostic evidence linking baseline and dynamic changes in ELF, LSM by VCTE, and LSM by MRE to cirrhosis progression, decompensation, HCC, and survival.

How to read a liver biopsy report (NAS 0–8 vs. F0–F4), 'At-Risk MASH' vs. 'At Risk of MASH', biopsy sampling variability, and pre-test fasting/confounder checklists.